Review Article

The Metabolic Syndrome and Mind-Body Therapies: A Systematic Review

Joel G. Anderson and Ann Gill Taylor

Center for the Study of Complementary and Alternative Therapies, University of Virginia School of Nursing, P.O. Box 800782, Charlottesville, VA 22908-0782, USA

Correspondence should be addressed to Ann Gill Taylor, agt@virginia.edu

Received 22 December 2010; Accepted 18 March 2011

Academic Editor: H. Boeing

Copyright © 2011 J. G. Anderson and A. G. Taylor. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The metabolic syndrome, affecting a substantial and increasing percentage of the worldwide population, is comprised of a cluster of symptoms associated with increased risk of type 2 diabetes, cardiovascular disease, and other chronic conditions. Mind-body modalities based on Eastern philosophy, such as yoga, tai chi, qigong, and meditation, have become increasingly popular worldwide. These complementary therapies have many reported benefits for improving symptoms and physiological measures associated with the metabolic syndrome. However, clinical trial data concerning the effectiveness of these practices on the syndrome as a whole have not been evaluated using a systematic and synthesizing approach. A systematic review was conducted to critically evaluate the data from clinical trials examining the efficacy of mind-body therapies as supportive care modalities for management of the metabolic syndrome. Three clinical trials addressing the use of mind-body therapies for management of the metabolic syndrome were identified. Findings from the studies reviewed support the potential clinical effectiveness of mind-body practices in improving indices of the metabolic syndrome.

1. Introduction

The last 50 years have seen a dramatic increase in metabolic disorders, including obesity and type 2 diabetes, with the number of individuals diagnosed with type 2 diabetes worldwide expected to surpass 360 million by 2030 [1]. This prevalence is rising given the epidemic of obesity, which is fueled, in part, by physical inactivity and unhealthy eating patterns [2]. The metabolic syndrome, which affects nearly 40% of the US population [3], is a complex condition characterized by multiple, interrelated metabolic abnormalities linked to insulin resistance [4] and exacerbated by aging [5]. Core features of the metabolic syndrome are insulin resistance, glucose intolerance, atherogenic dyslipidemia, visceral adiposity, and hypertension [6, 7]. The symptom cluster that defines the metabolic syndrome has been shown to contribute to the pathogenesis and progression of type 2 diabetes and its related disorders, cardiovascular disease (CVD), and other chronic conditions [4, 6–14].

Other abnormalities associated with the metabolic syndrome and linked to the pathogenesis and progression of chronic diseases include hypercoagulation, chronic inflammation, endothelial dysfunction, oxidative stress, and reduced bioavailability of insulin-like growth factor-1 [8, 15–17]. Increased sympathetic activity and reduced parasympathetic tone have been implicated in the pathogenesis of the metabolic syndrome and its related complications [15, 18]. In addition, there is mounting evidence that chronic psychological stress and negative mood states are strongly associated, in a bidirectional manner, with insulin resistance, glucose intolerance, central obesity, dyslipidemia, hypertension, and other components of the metabolic syndrome [19–25]. Likewise, prospective studies have shown that depression, a common comorbidity in individuals with the metabolic syndrome, increases subsequent risk for developing type 2 diabetes by two- to threefold [21, 26]. Sleep disturbance, which also increases with age [27] and has been implicated in the development of insulin resistance [28], has also been...
associated with an increased risk for both type 2 diabetes
[29] and its associated complications, as well as other
chronic conditions [30]. Given the dramatically increasing
prevalence, associated premature mortality, disability, com-
plications, and social and economic costs, management of
the metabolic syndrome is of importance to public health.

Modalities such as yoga, tai chi, qigong, and medita-
tion may represent adjuncts to the conventional care
and management of the metabolic syndrome. Records of these
practices extend back to ancient times in Asia, and many of
these forms, now referred to as mind-body therapies,
currently are practiced throughout the world. Use of mind-
body practices have increased in the US in recent years.
Around 20% of the population engage in some form of
mind-body practice based on data from the 2007 National
Health Interview Survey, with yoga, meditation, and deep
breathing exercises being the most popular [31]. Mind-
body modalities have demonstrated efficacy in improving
individual indices that comprise the symptom cluster that
defines the metabolic syndrome. A recent comprehensive
review found that yoga improved specific metabolic risk
factors, including blood pressure, lipoprotein profiles, body
mass index (BMI), and insulin sensitivity [32]. Clinical trials
have demonstrated the benefits of yoga in diabetes, hyperten-
sion, dyslipidemia, atherosclerosis, improving blood glucose
[33, 34], the insulin-glucose ratio, glycosylated hemoglobin
[34], and requirements for oral hypoglycemics and insulin
[33] as well as body weight and composition [32].

Growing evidence suggests that tai chi and qigong may
improve indices of glycemic control in people with diabetes
[35]. Qigong has been shown to reduce blood pressure
[36], insulin resistance, glucose intolerance, oxidative stress
[37], and other related indices of CVD risk [35, 36]. While
research is limited, findings suggest the use of qigong
programs for reducing stress, anxiety, and depression and
improving associated health outcomes, including promotion
of adequate sleep [38]. Randomized, controlled trials (RCTs)
of transcendental meditation, a modality restored from
ancient Vedic tradition in India and taught worldwide since
1957, have demonstrated blood pressure-lowering effects
similar to primary antihypertensive medications [39].

Although the mechanisms underlying the putative physi-
ologic and psychological effects of the practice of mind-body
modalities are not yet well understood, the observed changes
likely occur through a number of pathways. By reducing the
activation and reactivity of the sympathoadrenal system and
the hypothalamic pituitary adrenal (HPA) axis and promot-
ing feelings of well-being, mind-body therapies may alleviate
the effects of stress and foster multiple positive downstream
effects on neuroendocrine status, metabolic function, and
related inflammatory responses. Also, by directly activat-
ing the vagus nerve, mind-body practices may enhance
parasympathetic output and thereby shift the autonomic
nervous system balance from primarily sympathetic to
parasympathetic, leading to positive changes in cardiac-vagal
function, mood, energy state, and related neuroendocrine,
metabolic, and inflammatory responses [40]. The demands
of modern society may be responsible for higher levels of
chronic stress, leading to activation of the neurohormonal
system, specifically the sympathoadrenal system and HPA
axis that involves catecholamine release, vagal withdrawal,
cortisol secretion, and upregulation of the renin-angiotensin
system. While research remains limited, findings suggest
that the use of mind-body practices reduces stress, anxiety,
and depression and improves associated health outcomes.
These benefits may be particularly important for people at
risk of or with the metabolic syndrome, who may be more
vulnerable to compromised health-related quality of life,
poor psychosocial health, poor self-care practices, increased
healthcare costs, and adverse outcomes [41].

This systematic review critically evaluates the data exam-
ining the efficacy of mind-body therapies as supportive
care modalities for management of the metabolic syndrome,
focuses on studies of the cluster of symptoms that make
up the metabolic syndrome rather than on those studies that
have investigated only single components.

2. Methods

2.1. Data Sources. Electronic databases (MEDLINE, CIN-
AHL, and PubMed) were searched from the respective
inception dates through November 18, 2010, to locate po-
tentially relevant peer-reviewed articles using logical com-
binations of the following search terms: “mind-body,”
“metabolic syndrome,” “yoga,” “tai chi,” “qigong,” “mindful-
ness,” and “meditation.” Additionally, relevant journals and
the references of all located articles were manually searched
for other potentially relevant studies.

2.2. Study Selections. For the purposes of this systematic
review, mind-body therapies were limited to yoga, tai chi,
qigong, mindfulness-based techniques, and any form of
meditation. Studies that assessed one of the defined mind-
body therapies alone or as an adjuvant to conventional
treatment in human subjects with the metabolic syndrome
were included. Trials were excluded if the study examined
a mind-body modality as part of a complex intervention
(i.e., combining a mind-body therapy with another com-
plementary modality), was aimed at the development of
the methodology of mind-body therapy procedures without
clinical outcomes, reported no data or statistical compar-
isons, assessed healthy subjects, or was limited to only
components of the metabolic syndrome (i.e., hypertension
or insulin sensitivity alone). Abstracts were included, and
hard copies of all documents pertaining to the included
studies were obtained and read in full.

2.3. Data Extraction and Quality Assessment. Two indepen-
dent reviewers validated, extracted, and recorded relevant
study data using predefined criteria. Allocation conceal-
ment was assessed using the Cochrane classification, and the
quality of all studies was independently assessed using a
modification of the scoring criteria used for a previous
review of a biofield therapy by the authors [44]. Using this
method, a maximum of five points was awarded. One point
was given for a description of the trial as a randomized study,
one point for an appropriate method of randomization being
reported, one point for an appropriate control group, and

2.2. Study Selections. For the purposes of this systematic
review, mind-body therapies were limited to yoga, tai chi,
qigong, mindfulness-based techniques, and any form of
meditation. Studies that assessed one of the defined mind-
body therapies alone or as an adjuvant to conventional
treatment in human subjects with the metabolic syndrome
were included. Trials were excluded if the study examined
a mind-body modality as part of a complex intervention
(i.e., combining a mind-body therapy with another com-
plementary modality), was aimed at the development of
the methodology of mind-body therapy procedures without
clinical outcomes, reported no data or statistical compar-
isons, assessed healthy subjects, or was limited to only
components of the metabolic syndrome (i.e., hypertension
or insulin sensitivity alone). Abstracts were included, and
hard copies of all documents pertaining to the included
studies were obtained and read in full.

2.3. Data Extraction and Quality Assessment. Two indepen-
dent reviewers validated, extracted, and recorded relevant
study data using predefined criteria. Allocation conceal-
ment was assessed using the Cochrane classification, and the
quality of all studies was independently assessed using a
modification of the scoring criteria used for a previous
review of a biofield therapy by the authors [44]. Using this
method, a maximum of five points was awarded. One point
was given for a description of the trial as a randomized study,
one point for an appropriate method of randomization being
reported, one point for an appropriate control group, and
one point for the blinding of the evaluator. Given the nature of the interventions, blinding of the study participants is not possible and was not included in the scoring of the trials. An additional point was awarded for reporting the details concerning withdrawals and dropouts from the trial. Any discrepancies in the scoring of the trials were resolved by discussion between the two reviewers.

3. Results

3.1. Study Description. The searches identified 692 potentially relevant articles, of which 689 articles were excluded. This resulted in three trials being included in the paper. A schematic of the excluded studies as well as the reasons for exclusion are outlined in Figure 1, with key data from each study summarized in Table 1. One study was excluded because the comorbidities of the study population were too heterogeneous and not limited to the metabolic syndrome [45]. Another study was excluded because the intervention did not have a strong mind-body component and was related more to physical activity alone than to a mind-body modality [46]. An additional study was excluded because it was of a single-group, quasiexperimental design [41].

3.2. Study Quality. The quality scores of the included RCTs ranged between 2 and 5 out of possible 5 points. Of the three included trials, only one adequately described the methods of randomization and reported sufficient information regarding appropriate allocation concealment and assessor blinding [39]. Details of study dropouts and withdrawals were reported in two trials [39, 43].

3.3. Included Studies. Paul-Labrador and colleagues [39] (modified score = 5) conducted an RCT of transcendental meditation using a two-group, parallel design in individuals with coronary heart disease and the metabolic syndrome. Subjects (N = 103) were randomized to either a transcendental meditation or a health education program for 16 weeks. Both the meditation and health education interventions consisted of the same number and frequency of group meetings. The transcendental meditation intervention involved a highly standardized, traditional protocol, while the health education intervention was comprised of lectures and discussions involving risk factors for and the impact of lifestyle and environmental factors on CVD. Outcome measures included blood pressure, lipoprotein profile, insulin resistance using the homeostasis model assessment (HOMA), endothelial function using the brachial artery reactivity test (BART), heart rate variability (HRV), medical history, body mass index (BMI), hostility, depression, trait anxiety, trait anger, stress, plasma cholesterol, triglycerides, HDL cholesterol, plasma glucose, plasma insulin, and highsensitivity C-reactive protein (hs-CRP).

A significant difference in adjusted systolic blood pressure was observed at the end of the study in the transcendental meditation group versus the health education group (P = .04). No differences were found in lipoproteins, hs-CRP, or BMI. There was a trend toward an increase in physical activity in the health education group versus
| References                  | Design, allocation concealment | Modified score | Interventions (regimen) | Main outcome measures                                                                                         | Main results                                                                                                                                                                                                 | Comments                                                                                       |
|-----------------------------|--------------------------------|----------------|-------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Paul-Labrador et al., 2006 [39] | Parallel 2 groups Unmasked       | 5              | Transcendental meditation versus health education for 16 weeks | Blood pressure, lipoprotein profile, insulin resistance (HOMA), endothelial function (BART), HRV, medication history, BMI, hostility, depression, trait anxiety, trait anger, stress, plasma cholesterol, triglycerides, HDL-C, plasma glucose, plasma insulin, and hs-CRP | Significant difference in systolic and arterial blood pressure at exit No difference in lipoproteins, hs-CRP, BMI, or BART Improved glucose, insulin levels, and HRV in meditation group | Trend toward increase in physical activity in health education group Health education group more depressed and angry at entry and exit |
| Khatri et al., 2007 [42]     | Parallel 2 groups Unknown        | 2              | Usual care versus usual care plus yoga for 12 weeks           | BMI, waist circumference, blood pressure, blood glucose, HbA1c, triglycerides, HDL-C                           | Significant improvement in waist circumference, blood pressure, blood glucose, HbA1c, triglycerides, and HDL-C in yoga group                                                                                      |                                                                                                 |
| Cohen et al., 2008 [43]      | Parallel 2 groups Unknown        | 3              | Restorative yoga versus control                               | BMI, waist circumference, blood pressure, insulin sensitivity, plasma glucose, plasma insulin, triglycerides, HDL-C, LDL-C, demographics, PSS, Block 2005, physical activity, SF-36, CES-D, overall health (Likert scale) | Trend toward improved blood pressure, well-being, and stress in yoga group Nonsignificant changes in BMI in yoga group No difference in serological measures, diet, or physical activity | Yoga group reported being “very satisfied” with intervention, felt that practicing restorative yoga “very easy” or “moderately easy” |

* Classified by Cochrane criteria. HOMA: homeostasis model assessment; BART: brachial artery reactivity test; HRV: heart rate variability; BMI: body mass index; HDL-C: high-density lipoprotein-cholesterol; hs-CRP: high-sensitivity C-reactive protein; HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol; PSS: Perceived Stress Scale; Block 2005: food frequency questionnaire; CES-D: Center for Epidemiologic Study-Depression Scale; PSQ: Perceived Stress Questionnaire; SF-36 (measures physical and mental aspects of health).

the transcendental meditation group. The health education group was more depressed and angry at the beginning and end of the study period than was the transcendental meditation group. Improved plasma glucose and insulin levels were observed in the transcendental meditation group versus the health education group at the conclusion of the study period \((P = .01)\). No difference in endothelial function was observed. A significant difference in the change in the high-frequency HRV was observed in the transcendental meditation group versus the health education group at the
end of the study after adjusting for covariates \( (P = .02) \), with a trend toward a change in the measurements of total power and low-frequency HRV \( (P = .07) \).

Khatri and colleagues [42] (modified score = 2) evaluated the efficacy of a yoga intervention plus usual care versus usual care alone in individuals \( (N = 101) \) with the metabolic syndrome in a randomized study over the course of 12 weeks. Outcome measures included BMI, waist circumference, blood pressure, blood glucose, glycosylated hemoglobin \( (\text{HbA1c}) \), triglycerides, and HDL. Significant improvements in waist circumference, systolic and diastolic blood pressure, blood glucose, \( \text{HbA1c} \), triglycerides, and HDL \( (P < .001) \) were observed in the yoga group from baseline to the end of the study period. A comparison to the control group was not given.

Cohen and colleagues [43] (modified score = 3) examined the effects of a restorative yoga intervention using a parallel study design. The yoga intervention consisted of a 3-hour introduction class, followed by a 90-minute class two times per week for 5 weeks, and then one class weekly for 5 weeks. Subjects \( (n = 24) \) randomized to the yoga group were to practice 3 times per week outside of class, tracking activity in a log book. The control group received no intervention. Outcome measures included BMI, waist circumference, blood pressure, insulin sensitivity, plasma glucose, plasma insulin, triglycerides, LDL, HDL, demographic information, perceived stress (PSS), dietary information using a food frequency questionnaire (2005 Block questionnaire), physical activity, quality of life (SF-36), depression (CES-D), and a self-rating of overall health using a Likert scale. Trends toward improved blood pressure \( (P = .07) \), well-being \( (P < .12) \), and stress \( (P < .22) \) were observed, as well as nonsignificant changes in weight and BMI in the yoga group. There was no difference in any of the serological measures in either group at the end of the study. The yoga group reported a significant improvement in energy level \( (P < .009) \). No significant changes in diet or physical activity were reported. The yoga group reported being “very satisfied” with the intervention, with the majority \( (87\%) \) finding the practice of restorative yoga “very easy” or “moderately easy.” This study demonstrates the feasibility of recruiting overweight individuals with the metabolic syndrome for a yoga study.

4. Discussion

A very small number of clinical trials addressing the use of mind-body therapies for management of the metabolic syndrome were identified in the process of conducting this review. Though the studies support the potential clinical effectiveness of mind-body practices in improving indices of the metabolic syndrome, more studies are required given that the trials included had several limitations. In the study by Paul-Labrador and colleagues [39], a lack of a description of the psychosocial outcome measures used as well as baseline differences in depression and anger make the results difficult to interpret. Moreover, a usual care alone group was not included in the study, which is essential when making comparisons to the standard of care. The use of HOMA as a measure of insulin resistance is an indirect method that may have underestimated effects of the interventions in the reviewed studies. None of the studies indicated the use of ambulatory blood pressure monitoring over the course of the study. Measurement of blood pressure only at study intervals might have underestimated the efficacy of the mind-body interventions in lowering this key component/symptom of the metabolic syndrome. Only one of the reviewed studies did not include waist circumference as an outcome measure [39]. The study by Khatri and colleagues [42] was published as a brief correspondence, limiting the description of the study population, the methods, the intervention, and the results, including a comparison of the intervention with the control group. No rationale was given for the inconsistency in the duration and timing of the intervention over the course of the study period in the trial by Cohen and colleagues [43]. Additionally, this latter study had a small sample size limiting the statistical power of the results, a brief follow-up period that may have diminished the estimation of effects, and those participants in the yoga group may have been affected by the group dynamics of the yoga classes.

For the results of a clinical study to be useful, one must be able to replicate the trial; therefore, all aspects of the methodology and the intervention, as well as a detailed description of the results, must be reported. None of the included studies in this paper provided a clear rationale for the treatment specificity or duration. Given that the optimal dosage of mind-body therapies has yet to be determined, a description of the treatment duration and number of treatments should be included. While there remains a lack of rigorous trials that apply adequate methodology, including the use of blinding and placebo treatments, given that trials with inadequate levels of blinding are likely to show exaggerated treatment effects [47], the nature of mind-body therapies makes it seemingly impossible to blind subjects to the intervention or to develop a placebo.

Given the physiological outcomes associated with the metabolic syndrome, objective outcome measures such as lipoprotein profiles, circulating levels of glucose and insulin, and anthropometric measures are consistent across studies of the metabolic syndrome, which allows for comparison among studies. However, different subjective assessments were used in the included trials to determine subjective or psychosocial outcomes such as fatigue and health-related quality of life, making comparisons more challenging. This issue is not unique to the study of mind-body or complementary therapies. Indeed, RCTs often use various outcome measures of patient symptoms to quantify the same concepts, limiting comparison across studies [48]. Additionally, some patient-reported outcomes are likely not to be captured because of a lack of sensitivity of the instrument or to the floor and ceiling effects of some measures that do not assess symptom extremes adequately [48], a potential limitation acknowledged by Paul-Labrador and colleagues [39]. The Patient-Reported Outcomes Measurement Information System (PROMIS) Initiative aims to improve appreciably how these measures are selected and assessed in clinical research, including clinical trials [48]. As part of the NIH Roadmap Initiative, use of these measures supports the goals of the
PROMIS Initiative to revolutionize the way patient-reported outcome tools are used in clinical research and practice and to aid in transforming the nation’s medical research capabilities, speeding the movement of research [49].

Limitations of systematic reviews, including the current paper, relate to any potential incompleteness of the reviewed studies. This effect may result from publication bias given that negative studies tend to remain unpublished [50]. A further weakness of the current paper involves the limitations of the reviewed studies. Methodological shortcomings such as small sample size and inadequate reporting of methods and results leave the overall result inconclusive. The exclusion of studies focusing on clinical outcomes related to single components of the metabolic syndrome may be a limitation; however, the inclusion of trials examining only certain cardiometabolic measures would not provide reliable data on the clinical effectiveness of mind-body therapies in improving the symptom cluster that comprises the metabolic syndrome as a whole.

Mind-body therapies may carry practical advantages as therapeutic interventions for managing the symptom cluster associated with the metabolic syndrome. While several large trials have demonstrated the effectiveness of physical activity in improving outcomes of the metabolic syndrome, many individuals, such as those who are overweight and sedentary and at highest risk for the metabolic syndrome, may be unable or unwilling to participate in conventional types of physical activity (e.g., strength training and gym-based exercises) [41, 43]. Mind-body modalities are simple, economical, noninvasive therapies, easy to learn, and can be practiced easily by individuals who may experience potential limitations in mobility [51]. Requiring little in the way of equipment or professional personnel, mind-body therapies are relatively easy and inexpensive to practice. Moreover, mind-body therapies typically bring immediate positive benefits, including feelings of relaxation and tranquility. For example, even short-term qigong programs (20 days to 10 weeks) have been shown to result in significant improvements in sleep, mood, and other distressful symptoms, as well as cardiovascular health [35, 52], helping to encourage continued practice. Several studies indicate that qigong and other mind-body programs may reduce healthcare costs in both clinical and nonclinical populations [53, 54].

5. Conclusion

Clearly, there is a need to identify cost-effective prevention and management strategies for the metabolic syndrome that address the multiple interrelated factors underlying this complex, devastating, and rapidly increasing chronic condition. No such research has been conducted in this regard with respect to mind-body therapies. Current clinical practice guidelines indicate lifestyle modifications as the sole therapy for prehypertension, as well as other indicators of the metabolic syndrome [55]. Given the positive effects of mind-body therapies on cardiometabolic components, these modalities most likely would be of benefit to individuals with the metabolic syndrome. The current paper provides healthcare practitioners with information that could be used in decision-making about recommendations involving mind-body practices. In light of the important role of psychosocial factors in the development of insulin resistance, type 2 diabetes, and other chronic diseases, the influence of sympathetic activation in the pathogenesis of insulin resistant states and the bidirectional relationships of these and other insulin resistance-related risk factors and mind-body therapies may hold promise for both the prevention and treatment of the metabolic syndrome. Because RCTs remain the “gold standard” in biomedical research, this paper highlights the need for such trials of mind-body therapies with regard to the management of the metabolic syndrome, given the relative absence of such studies in the literature, as well as the mechanisms of action involved in mind-body therapies.

Acknowledgments

The authors would like to thank Jewel Holmberg, Kendra Gaarder, and Rochelle Jobes for their editorial assistance with this paper. This publication was made possible by Grant nos. 5-T32-AT000052 and 5-K07-AT002943 from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCCAM.

References

[1] World Health Organization, Prevalence of Diabetes Worldwide, vol. 2011, World Health Organization, Lyon, France, 2011.
[2] J. C. Seidell, “Obesity, insulin resistance and diabetes—a worldwide epidemic,” British Journal of Nutrition, vol. 83, supplement 1, pp. S5–S8, 2000.
[3] E. S. Ford, C. Li, and G. Zhao, “Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US,” Journal of Diabetes, vol. 2, no. 3, pp. 180–193, 2010.
[4] A. A. Rizvi, “Type 2 diabetes: epidemiologic trends, evolving pathogenetic concepts, and recent changes in therapeutic approach,” Southern Medical Journal, vol. 97, no. 11, pp. 1079–1087, 2004.
[5] H. M. Perry III, “The endocrinology of aging,” Clinical Chemistry, vol. 45, no. 8, pp. 1369–1376, 1999.
[6] B. O. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.
[7] M. P. Reilly and D. J. Rader, “The metabolic syndrome: more than the sum of its parts?” Circulation, vol. 108, no. 13, pp. 1546–1551, 2003.
[8] B. Isomaa, “A major health hazard: the metabolic syndrome,” Life Sciences, vol. 73, no. 19, pp. 2395–2411, 2003.
[9] E. Caglayan, F. Blaschke, Y. Takata, and W. A. Hsueh, “Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways,” Current Opinion in Pharmacology, vol. 5, no. 2, pp. 135–142, 2005.
[10] D. J. Brotman and J. P. Girod, “The metabolic syndrome: a tug-of-war with no winner,” Cleveland Clinic Journal of Medicine, vol. 69, no. 12, pp. 990–994, 2002.
[11] R. A. DeFronzo and E. Ferrannini, “Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, vol. 14, no. 3, pp. 173–194, 1991.

[12] D. E. Laakso, H. M. Lakk, L. K. Niskanen, G. A. Kaplan, J. T. Salonen, and T. A. Lakk, “Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study,” American Journal of Epidemiology, vol. 156, no. 11, pp. 1070–1077, 2002.

[13] N. Sattar, A. Gaw, O. Scherbakova et al., “Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study,” Circulation, vol. 108, no. 4, pp. 414–419, 2003.

[14] H. M. Lakk, D. E. Laakso, T. A. Lakk et al., “The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2709–2716, 2002.

[15] S. N. Stas, F. A. El-Atat, and J. R. Sowers, “Pathogenesis of hypertension in diabetes,” Reviews in Endocrine and Metabolic Disorders, vol. 5, no. 3, pp. 221–225, 2004.

[16] L. E. Wold, D. Muralikrishnan, C. B. Albano, F. L. Norby, M. Ebadi, and J. Ren, “Insulin-like growth factor 1 (IGF-1) supplementation prevents diabetes-induced alterations in coenzymes Q and O,” Acta Diabetologica, vol. 40, no. 2, pp. 85–90, 2003.

[17] S. B. Wheatcroft, I. L. Williams, A. M. Shah, and M. T. Kearney, “Pathophysiological implications of insulin resistance on vascular endothelial function,” Diabetic Medicine, vol. 20, no. 4, pp. 255–268, 2003.

[18] M. Esler, M. Rumantir, G. Wiesner, D. Kaye, J. Hastings, and G. Lambert, “Sympathetic nervous system and insulin resistance: from obesity to diabetes,” American Journal of Hypertension, vol. 14, no. 11, 2001.

[19] P. P. Vitaliano, J. M. Scanlan, J. Zhang, M. V. Savage, I. B. Hirsch, and I. C. Siegler, “A path model of chronic stress, the metabolic syndrome, and coronary heart disease,” Psychosomatic Medicine, vol. 64, no. 3, pp. 418–435, 2002.

[20] K. Räikkönen, K. A. Matthews, and L. H. Kuller, “The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?” Metabolism: Clinical and Experimental, vol. 51, no. 12, pp. 1573–1577, 2002.

[21] T. G. Pickering, D. Phil, L. Clemow, K. Davidson, and W. Gerin, “Behavioral cardiology—has its time finally arrived?” Mount Sinai Journal of Medicine, vol. 70, no. 2, pp. 101–112, 2003.

[22] P. Björntorp, “Body fat distribution, insulin resistance, and metabolic diseases,” Nutrition, vol. 13, no. 9, pp. 795–803, 1997.

[23] P. H. Black and L. D. Garbutt, “Stress, inflammation and cardiovascular disease,” Journal of Psychosomatic Research, vol. 52, no. 1, pp. 1–23, 2002.

[24] O. Chan, K. Inouye, M. C. Riddell, M. Vranic, and S. G. Matthews, “Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis,” Minerva Endocrinologia, vol. 28, no. 2, pp. 87–102, 2003.

[25] R. von Kanel, P. J. Mills, C. Fainman, and J. E. Dimsdale, “Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease?” Psychosomatic Medicine, vol. 63, no. 4, pp. 531–544, 2001.

[26] D. L. Musselman, E. Betan, H. Larsen, and L. S. Phillips, “Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment,” Biological Psychiatry, vol. 54, no. 3, pp. 317–329, 2003.

[27] P. N. Prinz, “Sleep and sleep disorders in older adults,” Journal of Clinical Neurophysiology, vol. 12, no. 2, pp. 139–146, 1995.

[28] T. Akerstedt and P. M. Nilsson, “Sleep as restitution: an introduction,” Journal of Internal Medicine, vol. 254, no. 1, pp. 6–12, 2003.

[29] C. Meisinger, M. Heier, and H. Loewel, “Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population,” Diabetologia, vol. 48, no. 2, pp. 235–241, 2005.

[30] A. B. Newman, P. L. Enright, T. A. Manolio, E. F. Haponik, and P. W. Wahl, “Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study,” Journal of the American Geriatrics Society, vol. 45, no. 1, pp. 1–7, 1997.

[31] P. M. Barnes, B. Bloom, and R. L. Nahin, “Complementary and alternative medicine use among adults and children: United States, 2007,” National Health Statistics Reports, no. 12, pp. 1–23, 2009.

[32] K. E. Innes, C. Bourguignon, and A. G. Taylor, “Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review,” Journal of the American Board of Family Practice, vol. 18, no. 6, pp. 491–519, 2005.

[33] B. K. Sahay, “Yoga and diabetes,” The Journal of the Association of Physicians of India, vol. 34, no. 9, pp. 645–648, 1986.

[34] S. Singh, V. Malhotra, K. P. Singh, S. V. Madhu, and O. P. Tandon, “Role of Yoga in modifying certain cardiovascular functions in type 2 diabetic patients,” Journal of Association of Physicians of India, vol. 52, pp. 203–206, 2004.

[35] L. Xin, Y. D. Miller, and W. J. Brown, “A qualitative review of the role of Qigong in the management of diabetes,” Journal of Alternative and Complementary Medicine, vol. 13, no. 4, pp. 427–433, 2007.

[36] M. S. Lee, K. W. Chen, K. M. Sancier, and E. Ernst, “Qigong for cancer treatment: a systematic review of controlled clinical trials,” Acta Oncologica, vol. 46, no. 6, pp. 717–722, 2007.

[37] F. M. Vera, J. M. Manzaneque, E. F. Maldonado et al., “Biochemical changes after a qigong program: lipids, serum enzymes, urea, and creatinine in healthy subjects,” Medical Science Monitor, vol. 13, no. 12, pp. CR560–CR566, 2007.

[38] M. S. Lee, M. H. Pittler, R. Guo, and E. Ernst, “Qigong for hypertension: a systematic review of randomized clinical trials,” Journal of Hypertension, vol. 25, no. 8, pp. 1525–1532, 2007.

[39] M. Paul-Labrador, D. Polk, J. H. Dwyer et al., “Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease,” Archives of Internal Medicine, vol. 166, no. 11, pp. 1218–1224, 2006.

[40] A. G. Taylor, L. E. Goehler, D. I. Galper, K. E. Innes, and T. T. Salonen, and T. A. Lakka, “Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2709–2716, 2002.

[41] F. M. Vera, J. M. Manzaneque, E. F. Maldonado et al., “Biochemical changes after a qigong program: lipids, serum enzymes, urea, and creatinine in healthy subjects,” Medical Science Monitor, vol. 13, no. 12, pp. CR560–CR566, 2007.

[42] M. S. Lee, M. H. Pittler, R. Guo, and E. Ernst, “Qigong for hypertension: a systematic review of randomized clinical trials,” Journal of Hypertension, vol. 25, no. 8, pp. 1525–1532, 2007.
[42] D. Khatri, K. C. Mathur, S. Gahlot, S. Jain, and R. P. Agrawal, “Effects of yoga and meditation on clinical and biochemical parameters of metabolic syndrome,” *Diabetes Research and Clinical Practice*, vol. 78, no. 3, pp. e9–e10, 2007.

[43] B. E. Cohen, A. A. Chang, D. Grady, and A. M. Kanaya, “Restorative yoga in adults with metabolic syndrome: a randomized, controlled pilot trial,” *Metabolic Syndrome and Related Disorders*, vol. 6, no. 3, pp. 223–229, 2008.

[44] J. G. Anderson and A. G. Taylor, “Effects of healing touch in clinical practice: a systematic review of randomized clinical trials,” *Journal of Holistic Nursing*. In press.

[45] R. L. Bijlani, R. P. Vempati, R. K. Yadav et al., “A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus,” *Journal of Alternative and Complementary Medicine*, vol. 11, no. 2, pp. 267–274, 2005.

[46] M. Vázquez-Vandyck, S. Roman, J. L. Vázquez et al., “Effect of breathwalk on body composition, metabolic and mood state in chronic hepatitis C patients with insulin resistance syndrome,” *World Journal of Gastroenterology*, vol. 13, no. 46, pp. 6213–6218, 2007.

[47] D. G. Altman, K. F. Schulz, D. Moher et al., “The revised CONSORT statement for reporting randomized trials: explanation and elaboration,” *Annals of Internal Medicine*, vol. 134, no. 8, pp. 663–694, 2001.

[48] S. F. Garcia, D. Cella, S. B. Clauser et al., “Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative,” *Journal of Clinical Oncology*, vol. 25, no. 32, pp. 5106–5112, 2007.

[49] Patient Reported Outcomes Measurement Information System (PROMIS), vol. 2010, http://www.nihpromis.org/Documents/PROMIS_The_First_Four_Years.pdf.

[50] M. S. Lee, M. H. Pittler, and E. Ernst, “Effects of reiki in clinical practice: a systematic review of randomised clinical trials,” *International Journal of Clinical Practice*, vol. 62, no. 6, pp. 947–954, 2008.

[51] Y. Yang, J. Verkuilen, K. S. Rosengren et al., “Effects of a Taiji and Qigong intervention on the antibody response to influenza vaccine in older adults,” *American Journal of Chinese Medicine*, vol. 35, no. 4, pp. 597–607, 2007.

[52] M. S. Lee, M. S. Lee, H. J. Kim, and S. R. Moon, “Qigong reduced blood pressure and catecholamine levels of patients with essential hypertension,” *International Journal of Neuroscience*, vol. 113, no. 12, pp. 1691–1701, 2003.

[53] R. Bonadonna, “Meditation’s impact on chronic illness,” *Holistic Nursing Practic*, vol. 17, no. 6, pp. 309–319, 2003.

[54] K. G. Walton, R. H. Schneider, J. W. Salerno, and S. I. Nidich, “Psychosocial stress and cardiovascular disease part 3: clinical and policy implications of research on the Transcendental Meditation program,” *Behavioral Medicine*, vol. 30, no. 4, pp. 173–183, 2005.

[55] M. V. Rainforth, R. H. Schneider, S. I. Nidich, C. Gaylord-King, J. W. Salerno, and J. W. Anderson, “Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis,” *Current Hypertension Reports*, vol. 9, no. 6, pp. 520–528, 2007.